Combination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejection

Area of Science:

• Ophthalmology
• Nanomedicine
• Immunology

Background:

• High-risk corneal transplantation has a high graft rejection rate (>50%) despite intensive immunosuppression.
• Effective anti-angiogenesis therapy for preventing graft rejection remains a clinical challenge.

Purpose of the Study:

• To engineer and evaluate controlled-release nanomedicine formulations for preventing high-risk corneal transplant rejection.
• To assess the efficacy of single-agent immunosuppressant nanoparticles and combination therapy with anti-angiogenesis drugs.

Main Methods:

• Development of controlled-release nanomedicine formulations containing immunosuppressants (nanoparticles) and anti-angiogenesis drugs (nanowafer).
• Evaluation of nanomedicine efficacy in a clinically relevant rat model of high-risk corneal transplantation.
• Assessment of graft survival rates following subconjunctival injection of nanomedicine formulations.

Main Results:

• A single subconjunctival injection of immunosuppressant nanoparticles alone prevented graft rejection for 6 months, achieving ~70% graft survival.
• Combination therapy with immunosuppressant nanoparticles and anti-VEGF nanowafer significantly enhanced efficacy, with >85% graft survival.
• Untreated corneal grafts were universally rejected within 2 weeks post-surgery.

Conclusions:

• Combination nanomedicine strategy incorporating immunosuppressants and anti-angiogenesis drugs significantly improves outcomes in high-risk corneal transplantation.
• This approach enhances ocular drug delivery, increases graft survival rates, and addresses patient compliance and toxicity concerns.